Literature DB >> 17360833

Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride).

Ian Midgley1, Karen Fitzpatrick, Lynne M Taylor, Tara L Houchen, Simon J Henderson, Sarah J Wright, Zbigniew R Cybulski, Brian A John, Alan McBurney, David W Boykin, Kerri L Trendler.   

Abstract

DB289 (pafuramidine maleate; 2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) is a prodrug of DB75 (furamidine dihydrochloride; 2,5-bis(4-guanylphenyl)furan dihydrochloride), an aromatic dication related to pentamidine that has demonstrated good efficacy against African trypanosomiasis, Pneumocystis carinii pneumonia, and malaria, but lacks adequate oral availability. The pharmacokinetics and metabolism of 14C-DB289 have been investigated in rat and monkey after oral and intravenous administration. Oral doses were well absorbed (approximately 50-70%) and effectively converted to DB75 in both species but subject to first-pass metabolism and hepatic retention, limiting its systemic bioavailability to 10 to 20%. Clearance of DB289 approximated the liver plasma flow and its large volume of distribution was consistent with extensive tissue binding. Plasma protein binding of DB289 was 97 to 99% in four animal species and humans, but that of DB75 was noticeably less and more species- and concentration-dependent. Together, prodrug and active metabolite accounted for less than 20% of the plasma radioactivity after an oral dose, but DB75 was the major radiochemical component in key organs such as brain and liver and was largely responsible for the persistence of 14C in the body. The predominant route of excretion of radioactivity was via the feces, although biliary secretion was not particularly extensive. High-performance liquid chromatography and liquid chromatography-mass spectrometry investigations showed that the formation of DB75 from the prodrug involved the sequential loss of the two N-methoxy groups, either directly or by O-demethylation followed by reduction of the resulting oxime to the amidine. It was estimated that almost half of an oral dose of DB289 to rats and about one-third of that to monkeys was metabolized to DB75.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360833     DOI: 10.1124/dmd.106.013391

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  17 in total

1.  A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair.

Authors:  Grace Zhixia Yan; Claudia N Generaux; Miyoung Yoon; Rachel B Goldsmith; Richard R Tidwell; James E Hall; Carol A Olson; Harvey J Clewell; Kim L R Brouwer; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2011-09-27       Impact factor: 3.922

2.  CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime].

Authors:  Michael Zhuo Wang; Janelle Y Saulter; Etsuko Usuki; Yen-Ling Cheung; Michael Hall; Arlene S Bridges; Greg Loewen; Oliver T Parkinson; Chad E Stephens; James L Allen; Darryl C Zeldin; David W Boykin; Richard R Tidwell; Andrew Parkinson; Mary F Paine; James Edwin Hall
Journal:  Drug Metab Dispos       Date:  2006-09-22       Impact factor: 3.922

3.  Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue.

Authors:  Nathan D Pfeifer; Kevin B Harris; Grace Zhixia Yan; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2013-08-29       Impact factor: 3.922

4.  Application of monoclonal antibodies to measure metabolism of an anti-trypanosomal compound in vitro and in vivo.

Authors:  Rachel Beaulieu Goldsmith; Danny R Gray; Zhixia Yan; Claudia N Generaux; Richard R Tidwell; Howard M Reisner
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

5.  In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness.

Authors:  Tanja Wenzler; Sihyung Yang; Donald A Patrick; Olivier Braissant; Mohamed A Ismail; Richard R Tidwell; David W Boykin; Michael Zhuo Wang; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

6.  Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.

Authors:  Tanja Wenzler; Sihyung Yang; Olivier Braissant; David W Boykin; Reto Brun; Michael Zhuo Wang
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

7.  A role for water molecules in DNA-ligand minor groove recognition.

Authors:  Binh Nguyen; Stephen Neidle; W David Wilson
Journal:  Acc Chem Res       Date:  2009-01-20       Impact factor: 22.384

8.  Sequence and length dependent thermodynamic differences in heterocyclic diamidine interactions at AT base pairs in the DNA minor groove.

Authors:  Yang Liu; Arvind Kumar; David W Boykin; W David Wilson
Journal:  Biophys Chem       Date:  2007-09-06       Impact factor: 2.352

9.  Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine.

Authors:  Michael Zhuo Wang; Judy Qiju Wu; Arlene S Bridges; Darryl C Zeldin; Sally Kornbluth; Richard R Tidwell; James Edwin Hall; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2007-08-20       Impact factor: 3.922

10.  Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites.

Authors:  Myaing M Nyunt; Craig W Hendrix; Rahul P Bakshi; Nirbhay Kumar; Theresa A Shapiro
Journal:  Am J Trop Med Hyg       Date:  2009-04       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.